title: Post-transplant lymphoproliferative disorders after heart or kidney transplantation at a single centre: presentation and response to treatment.
abstract: Post-transplant lymphoproliferative disorders (PTLD) is a serious complication after solid organ transplantation. Reduction of immunosuppression (RI) alone is not able to control the disease. We report a prospective analysis of 30 patients with PTLD after heart or kidney transplantation. Only 5 of 30 patients, treated solely with RI, obtained a complete response. Five patients were treated heterogeneously; in the remaining 20, the efficacy and safety of a weekly anthracycline-based chemotherapy were assessed. Sixteen patients obtained a complete remission. One death was related to treatment. With a median follow-up of 36 months, 3-year overall survival was 63.3% and 57% for the entire group and the chemotherapy-treated group, respectively. Moreover, 4 second neoplasms were observed in the chemotherapeutic group. In this study, we demonstrated that most PTLD need other treatment than RI and a weekly regimen is manageable and has a favourable impact on long-term survival.
authors.affiliation: Division of Medical Oncology, Istituto Oncologico Veneto, IRCCS, Padua, Italy. savina.aversa@ioveneto.it
authors.forename: S M L
authors.initials: SM
authors.lastname: Aversa
authors.forename: S
authors.initials: S
authors.lastname: Stragliotto
authors.forename: D
authors.initials: D
authors.lastname: Marino
authors.forename: F
authors.initials: F
authors.lastname: Calabrese
authors.forename: P
authors.initials: P
authors.lastname: Rigotti
authors.forename: F
authors.initials: F
authors.lastname: Marchini
authors.forename: A
authors.initials: A
authors.lastname: Gambino
authors.forename: G
authors.initials: G
authors.lastname: Feltrin
authors.forename: C
authors.initials: C
authors.lastname: Boso
authors.forename: F
authors.initials: F
authors.lastname: Canova
authors.forename: C
authors.initials: C
authors.lastname: Soldà
authors.forename: R
authors.initials: R
authors.lastname: Mazzarotto
authors.forename: P
authors.initials: P
authors.lastname: Burra
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D005260:Female; D016027:Heart Transplantation / Q000009:adverse effects*; D006689:Hodgkin Disease / Q000628:therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D016030:Kidney Transplantation / Q000009:adverse effects*; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy; D008232:Lymphoproliferative Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000209:etiology; D011446:Prospective Studies; D015996:Survival Rate
chemical_list: D007166:Immunosuppressive Agents